Background: To conduct a comprehensive performance evaluation of a fully auto-
A previous study demonstrated that PAP is useful for predicting the risk of perioperative VTE and for identifying patients with a high risk of fatal perioperative PE. 12 tPAI-C is a complex of t-PA with its type 1 inhibitor (PAI-1) which has been reported to be of practical value in assessing risk of MI and VTE for both genders, especially for smokers or diabetes mellitus patients. 13, 14 PAI-1 is synthesized from the endothelial cells as an active molecule, but it then spontaneously converts to a latent form, which can be partially reactivated in vitro. 15 Active form is secreted by cells and forms a stoichiometric 1:1 complex with the PA. Relative to the other serpins, active conformation of the PAI-1 is the least stable. 15 But most studies revealed that active PAI-1 is a potential marker of VTE, in contrast to PAI-1 antigen. But the measurement of active PAI-1 is complex in vitro. Therefore, we choose the marker of tPAI-C. In sum, TM, TAT, PAP, and tPAI-C all have potential clinical usefulness for the diagnosis, monitoring, and clinical prognosis of thrombus. However, their clinical application is limited because ELISA, which is the classical detection method for these factors, is time-consuming and has poor repeatability.
The HISCL-5000 chemiluminescence analyzer has the advantage of good repeatability, high sensitivity, high specificity, and simple operation. We have evaluated the clinical performance of this analyzer in this report.
| MATERIAL S AND ME THOD

| Samples
Commercially available normal and pathological lyophilized plasma 
| Analyzer
The HISCL-5000 (Sysmex Corporation, Kobe, Japan) instrument is a fully automated analyzer. The TM, TAT, PAP, and tPAI-C assays are one-step or two-step double-antigen sandwich qualitative chemiluminescence enzyme immunoassays performed on a fully automated analyzer (HISCL-5000; Sysmex Corporation, Kobe, Japan). Samples were tested according to the manufacturer's instructions with a total assay time of 17 minutes.
| Assay
| Precision testing
System precision for TM, TAT, PAP, and tPAI-C assays was based on the EP05-A3 protocol of the CLSI. 16 Intraassay variability was 
| Carryover
For each test, two patient samples were selected: a sample with a low-test result and a sample with a high-test result. These samples were further divided into 3 "low" aliquots (L) and 3 "high" aliquots (H). Aliquots were loaded into the analyzer in the following order:
H1, H2, H3, L1, L2, and L3. The carryover rate was calculated using the formula CR = (L1−L3)/(H3−L3) × 100%.
| Linearity analysis
Calibration curve linearity was determined using serial dilutions of a high-concentration pool (H) and a low-concentration pool (L).
Six equally spaced concentration pools were prepared as follows:
5H, 4H + L, 3H + 2L, 2H + 3L, H + 4L, and 5L. Each dilution was analyzed in duplicate. The concentration of each pool was defined by the following formula, where the concentration of Pool L is C L , the volume of Pool L is V L , the concentration of Pool H is C H , and the volume of Pool H is
Outliers were identified according to the CLSI EP06-A guidelines. 17 Polynomial regression analysis was also performed.
| REFEREN CE R ANG E S
Normal reference ranges were verified by testing samples from 
| S TAB ILIT Y TE S TING
Sample stability was evaluated by testing aliquots of patient samples placed for 0, 1, 3, 5, and 7 days at room temperature and in 4°C and −20°C environments.
| INTERFEREN CE S TUDIE S
Interference studies were performed to determine whether TM, TAT, PAP, and tPAI-C measurements were affected by other sub- 
| Statistical analysis
The results are expressed as the mean value with SD when the data were normally distributed. Otherwise, the results are expressed as the median value with range. Statistical analysis was performed using SPSS 19.0 software (IBM, New York, USA).
| RE SULTS
| Precision
Intraassay variability was determined, for each test by evaluating three levels of patient samples (normal, deviant, and very deviant)
21 times in the same day. As shown in Table 1 , the coefficients of variation (CV%), calculated as standard deviations divided by mean values, were below 4.5% for all tested parameters in both the normal and abnormal ranges. F I G U R E 2 Sample stability for thrombomodulin, thrombin-antithrombin, plasmin-α2-antiplasmin, and t-PA: PAI-1 complex
Interference studies of hemoglobin, triglycerides, and bilirubin on low level of thrombomodulin, thrombin-antithrombin, plasmin-α2-antiplasmin, and t-PA: PAI-1 complex
| D ISCUSS I ON
The classical detection method for TM, TAT, PAP, and tPAI-C is enzyme-linked immunosorbent assay (ELISA), which is gold standard method. But ELISA is time-consuming and has poor repeatability. With the development of high-sensitivity chemiluminescence immunoassay, we can test these factors automatically. Therefore, we performed analytical verification of TM, TAT, PAP, and tPAI-C using a high-sensitivity chemiluminescence analyzer according to the specifications of the Clinical and Laboratory Standards Institute (CLSI).
The reference intervals provided by the manufacturer were verified successfully for all parameters except for tPAI-C, for which reference intervals should be established according to gender.
Sample stability assessment revealed that TM is stable for 2 days at room temperature but lacks stability at colder temperatures, whereas TAT is stable for 5 days in 4°C and −20°C but has poor stability at room temperature. PAP and tPAI-C are both stable for 3 days at all three temperatures. Therefore, samples should be analyzed after centrifugation as soon as possible, and frozen preservation is not recommended.
In conclusion, verification data for precision, carryover, linearity, and interference revealed that the performance of the analyzer tested here is acceptable. However, the reference interval of tPAI-C should be established by each laboratory, and a comparison using another method should be performed in the future.
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